Highlight Investment Research is an independent and privately owned organization, has come a long way and today has emerged as a premium Indian stock & commodities consultancy, with an absolute focus on business and a commitment to provide “Real value for money to all its clients”.
The competition for Herceptin biosimilar is heating up in Europe after The European Medicines Agency (EMA) has recommended approval to Pfizer’s Trastuzumab biosimilar. Biocon and its partner Mylan have also submitted their copy of Herceptin biosimilar in Europe and have received approval in the US.
Yesterday, EMA recommended approval to Pfizer’s Trastuzumab biosimilar branded as Trazimera. The committee for medicinal products for human use (CHMP) has recommended marketing authorization to Trazimera to European Commission (EC). The EC will review the CHMP’s positive opinion before deciding whether to grant Pfizer marketing authorization. Trazimera is indicted in the treatment of types of cancers.
No comments